EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket
Tags :EraCal
EraCal, a Swiss biotech developing an anti-obesity drug, aims to raise CHF 15m in a Series A round next year, according to Mergermarket
Legalcommunity.ch
Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).
For further information, please visit the Group’s website www.lcpublishinggroup.com
